ASCO 2022 | The clinical potential of cellular therapeutics in melanoma
Allison Betof Warner, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the clinical potential of cellular therapeutics, particularly within the field of tumor infiltrating lymphocytes (TILs) and treating melanoma. Recently, promising results have been observed for PD-1 refractory melanoma, with durable response rates in the 30-35% range, highlighting the likelihood of the near future approval of cellular therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Transcript (edited for clarity)
So we gave an ASCO Education session yesterday on the clinical potential of cellular therapeutics. Really focused predominantly on TIL cell therapy in melanoma. Really exciting time in TIL therapy. We’ve really seen now some promising results, particularly for PD-1 refractory melanoma, with response rates in the 30 to 35% range. Really also promising from this one time treatment is that these responses seem to be durable, and for us, particularly in the post checkpoint refractory setting, that’s really exciting because there haven’t been too many treatment options, particularly that have durable response rates...
So we gave an ASCO Education session yesterday on the clinical potential of cellular therapeutics. Really focused predominantly on TIL cell therapy in melanoma. Really exciting time in TIL therapy. We’ve really seen now some promising results, particularly for PD-1 refractory melanoma, with response rates in the 30 to 35% range. Really also promising from this one time treatment is that these responses seem to be durable, and for us, particularly in the post checkpoint refractory setting, that’s really exciting because there haven’t been too many treatment options, particularly that have durable response rates. So, I think many of us are optimistic that we may see an approval of cellular therapy in the next year or so, and certainly an abundance of trials that are opening as we speak in this space.
Read more...
